Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study

R. Pieters, P. De Lorenzo, P. Ancliffe, LA. Aversa, B. Brethon, A. Biondi, M. Campbell, G. Escherich, A. Ferster, RA. Gardner, RS. Kotecha, B. Lausen, CK. Li, F. Locatelli, A. Attarbaschi, C. Peters, JE. Rubnitz, LB. Silverman, J. Stary, T....

. 2019 ; 37 (25) : 2246-2256. [pub] 20190708

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023704

PURPOSE: Infant acute lymphoblastic leukemia (ALL) is characterized by KMT2A (MLL) gene rearrangements and coexpression of myeloid markers. The Interfant-06 study, comprising 18 national and international study groups, tested whether myeloid-style consolidation chemotherapy is superior to lymphoid style, the role of stem-cell transplantation (SCT), and which factors had independent prognostic value. MATERIALS AND METHODS: Three risk groups were defined: low risk (LR): KMT2A germline; high risk (HR): KMT2A-rearranged and older than 6 months with WBC count 300 × 109/L or more or a poor prednisone response; and medium risk (MR): all other KMT2A-rearranged cases. Patients in the MR and HR groups were randomly assigned to receive the lymphoid course low-dose cytosine arabinoside [araC], 6-mercaptopurine, cyclophosphamide (IB) or experimental myeloid courses, namely araC, daunorubicin, etoposide (ADE) and mitoxantrone, araC, etoposide (MAE). RESULTS: A total of 651 infants were included, with 6-year event-free survival (EFS) and overall survival of 46.1% (SE, 2.1) and 58.2% (SE, 2.0). In West European/North American groups, 6-year EFS and overall survival were 49.4% (SE, 2.5) and 62.1% (SE, 2.4), which were 10% to 12% higher than in other countries. The 6-year probability of disease-free survival was comparable for the randomized arms (ADE+MAE 39.3% [SE 4.0; n = 169] v IB 36.8% [SE, 3.9; n = 161]; log-rank P = .47). The 6-year EFS rate of patients in the HR group was 20.9% (SE, 3.4) with the intention to undergo SCT; only 46% of them received SCT, because many had early events. KMT2A rearrangement was the strongest prognostic factor for EFS, followed by age, WBC count, and prednisone response. CONCLUSION: Early intensification with postinduction myeloid-type chemotherapy courses did not significantly improve outcome for infant ALL compared with the lymphoid-type course IB. Outcome for infant ALL in Interfant-06 did not improve compared with that in Interfant-99.

Australian and New Zealand Children's Haematology Oncology Group Perth Australia University of Western Australia Perth Western Australia Australia

Berlin Frankfurt Münster Group Germany Kiel Germany

Children Cancer Research Institute Vienna Austria

Chilean National Pediatric Oncology Group Santiago Chile

Czech Working Group for Pediatric Hematology Prague Czech Republic

Dana Farber Cancer Institute Boston MA

Dutch Childhood Oncology Group Utrecht the Netherlands Princess Maxima Center for Pediatric Oncology Utrecht the Netherlands

European Organisation for Research and Treatment of Cancer Children Leukemia Group Brussels Belgium

French Acute Lymphoblastic Leukemia Study Group Paris France

GATLA Buenos Aires Argentina

German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia Hamburg Germany

Polish Pediatric Leukemia Lymphoma Study Group Zabrze Medical University of Silesia Katowice Poland

Rigshospitalet University of Copenhagen Copenhagen Denmark

Seattle Children's Hospital and Research Institute Seattle WA

St Anna Children's Hospital Medical University of Vienna Vienna Austria

St Jude Children's Research Hospital Memphis TN

The Chinese University of Hong Kong Shatin Hong Kong Special Administrative Region People's Republic of China

United Kingdom Children Cancer Study Group London United Kingdom

University of Milano Bicocca Monza Italy

University of Milano Bicocca Monza Italy Istituto di Ricovero e Cura a Carattere Scientifico Bambino Gesù Children's Hospital Rome Italy University of Pavia Pavia Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023704
003      
CZ-PrNML
005      
20201214130906.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.19.00261 $2 doi
035    __
$a (PubMed)31283407
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Pieters, Rob $u Dutch Childhood Oncology Group, Utrecht, the Netherlands. Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands.
245    10
$a Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study / $c R. Pieters, P. De Lorenzo, P. Ancliffe, LA. Aversa, B. Brethon, A. Biondi, M. Campbell, G. Escherich, A. Ferster, RA. Gardner, RS. Kotecha, B. Lausen, CK. Li, F. Locatelli, A. Attarbaschi, C. Peters, JE. Rubnitz, LB. Silverman, J. Stary, T. Szczepanski, A. Vora, M. Schrappe, MG. Valsecchi,
520    9_
$a PURPOSE: Infant acute lymphoblastic leukemia (ALL) is characterized by KMT2A (MLL) gene rearrangements and coexpression of myeloid markers. The Interfant-06 study, comprising 18 national and international study groups, tested whether myeloid-style consolidation chemotherapy is superior to lymphoid style, the role of stem-cell transplantation (SCT), and which factors had independent prognostic value. MATERIALS AND METHODS: Three risk groups were defined: low risk (LR): KMT2A germline; high risk (HR): KMT2A-rearranged and older than 6 months with WBC count 300 × 109/L or more or a poor prednisone response; and medium risk (MR): all other KMT2A-rearranged cases. Patients in the MR and HR groups were randomly assigned to receive the lymphoid course low-dose cytosine arabinoside [araC], 6-mercaptopurine, cyclophosphamide (IB) or experimental myeloid courses, namely araC, daunorubicin, etoposide (ADE) and mitoxantrone, araC, etoposide (MAE). RESULTS: A total of 651 infants were included, with 6-year event-free survival (EFS) and overall survival of 46.1% (SE, 2.1) and 58.2% (SE, 2.0). In West European/North American groups, 6-year EFS and overall survival were 49.4% (SE, 2.5) and 62.1% (SE, 2.4), which were 10% to 12% higher than in other countries. The 6-year probability of disease-free survival was comparable for the randomized arms (ADE+MAE 39.3% [SE 4.0; n = 169] v IB 36.8% [SE, 3.9; n = 161]; log-rank P = .47). The 6-year EFS rate of patients in the HR group was 20.9% (SE, 3.4) with the intention to undergo SCT; only 46% of them received SCT, because many had early events. KMT2A rearrangement was the strongest prognostic factor for EFS, followed by age, WBC count, and prednisone response. CONCLUSION: Early intensification with postinduction myeloid-type chemotherapy courses did not significantly improve outcome for infant ALL compared with the lymphoid-type course IB. Outcome for infant ALL in Interfant-06 did not improve compared with that in Interfant-99.
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a cyklofosfamid $x aplikace a dávkování $7 D003520
650    _2
$a cytarabin $x aplikace a dávkování $7 D003561
650    _2
$a daunomycin $x aplikace a dávkování $7 D003630
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a etoposid $x aplikace a dávkování $7 D005047
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genová přestavba $7 D015321
650    _2
$a zárodečné mutace $7 D018095
650    _2
$a histonlysin-N-methyltransferasa $x genetika $7 D011495
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a merkaptopurin $x aplikace a dávkování $7 D015122
650    _2
$a mitoxantron $x aplikace a dávkování $7 D008942
650    _2
$a protoonkogenní protein MLL $x genetika $7 D051788
650    _2
$a akutní lymfatická leukemie $x farmakoterapie $x genetika $7 D054198
650    _2
$a míra přežití $7 D015996
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a De Lorenzo, Paola $u University of Milano-Bicocca, Monza, Italy.
700    1_
$a Ancliffe, Philip $u United Kingdom Children Cancer Study Group, London, United Kingdom.
700    1_
$a Aversa, Luis Alberto $u GATLA, Buenos Aires, Argentina.
700    1_
$a Brethon, Benoit $u French Acute Lymphoblastic Leukemia Study Group, Paris, France.
700    1_
$a Biondi, Andrea $u University of Milano-Bicocca, Monza, Italy. Istituto di Ricovero e Cura a Carattere Scientifico Bambino Gesù Children's Hospital, Rome, Italy. University of Pavia, Pavia, Italy.
700    1_
$a Campbell, Myriam $u Chilean National Pediatric Oncology Group, Santiago, Chile.
700    1_
$a Escherich, Gabriele $u German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia, Hamburg, Germany.
700    1_
$a Ferster, Alina $u European Organisation for Research and Treatment of Cancer Children Leukemia Group, Brussels, Belgium.
700    1_
$a Gardner, Rebecca A $u Seattle Children's Hospital and Research Institute, Seattle, WA.
700    1_
$a Kotecha, Rishi Sury $u Australian and New Zealand Children's Haematology/Oncology Group, Perth, Australia. University of Western Australia, Perth, Western Australia, Australia.
700    1_
$a Lausen, Birgitte $u Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
700    1_
$a Li, Chi Kong $u The Chinese University of Hong Kong, Shatin, Hong Kong, Special Administrative Region, People's Republic of China.
700    1_
$a Locatelli, Franco $u University of Milano-Bicocca, Monza, Italy. Istituto di Ricovero e Cura a Carattere Scientifico Bambino Gesù Children's Hospital, Rome, Italy. University of Pavia, Pavia, Italy.
700    1_
$a Attarbaschi, Andishe $u St Anna Children's Hospital, Medical University of Vienna, Vienna, Austria.
700    1_
$a Peters, Christina $u Children Cancer Research Institute, Vienna, Austria.
700    1_
$a Rubnitz, Jeffrey E $u St Jude Children's Research Hospital, Memphis, TN.
700    1_
$a Silverman, Lewis B $u Dana-Farber Cancer Institute, Boston, MA.
700    1_
$a Stary, Jan $u Czech Working Group for Pediatric Hematology, Prague, Czech Republic.
700    1_
$a Szczepanski, Tomasz $u Polish Pediatric Leukemia/Lymphoma Study Group, Zabrze, Medical University of Silesia, Katowice, Poland.
700    1_
$a Vora, Ajay $u United Kingdom Children Cancer Study Group, London, United Kingdom.
700    1_
$a Schrappe, Martin $u Berlin-Frankfurt-Münster Group Germany, Kiel, Germany.
700    1_
$a Valsecchi, Maria Grazia $u University of Milano-Bicocca, Monza, Italy.
773    0_
$w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 37, č. 25 (2019), s. 2246-2256
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31283407 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214130904 $b ABA008
999    __
$a ok $b bmc $g 1596023 $s 1114380
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 37 $c 25 $d 2246-2256 $e 20190708 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace